Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: AVTX stock price vs KMI: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at KMI's multiple
Needs KMI P/S.
Implied fair value · at AVTX's multiple
Needs AVTX P/S.
Metric by metric
Price unavailable
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: AVTX FY 2025 (ended Dec 31, 2025) · KMI FY 2025 (ended Dec 31, 2025).
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
AVALO THERAPEUTICS, INC. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
KINDER MORGAN, INC. · implied price per share
Bear
-$0.37
Base
$1.49
Bull
$4.60
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
-0.06x
1.03x
Net debt / EBITDA
Leverage against operating earnings
1.33x
5.42x
Cash and equivalents
Liquid reserves on the balance sheet
$98.34M
$63.00M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
CytomX Therapeutics, Inc.
AVTX vs CTMX
IDEAYA Biosciences, Inc.
AVTX vs IDYA
Ocugen, Inc.
AVTX vs OCGN
CLOVER HEALTH INVESTMENTS, CORP. /DE
AVTX vs CLOV
Citius Pharmaceuticals, Inc.
AVTX vs CTXR
WILLIAMS COMPANIES, INC.
AVTX vs WMB
ONEOK INC /NEW/
AVTX vs OKE
ENBRIDGE INC
AVTX vs ENB
New Fortress Energy Inc.
AVTX vs NFE
-$5.17M
$32.00B
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
